Statement: all the primary trial patients achieved either disappearance of all target lesions, greater than or equal to 0.3 times decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.
Primary_evidence: Outcome Measurement:    Complete Response + Partial Response + Stable Disease > 24 Weeks   Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.   A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks.   Time frame: 24 weeks Results 1:    Arm/Group Title: Sorafenib and Anastrozole   Arm/Group Description: All patients receive sorafenib and anastrozole.   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: participants  35